Study summary
An under-the-skin version of mosunetuzumab worked as well with less cytokine release
61.7%complete response rate
What was tested
A fixed-length course of mosunetuzumab given as a shot under the skin, compared with a group given it by IV, for follicular lymphoma after at least two earlier treatments.
What they found
- Complete response rate was 61.7%, with a median complete response lasting 34.6 months.
- Cytokine release syndrome occurred in 29.8% vs 44.4% with the IV version.
What it means
A more convenient way to give the drug, which may make it easier to use outside large cancer centers.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.